A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Follitropin delta (Primary) ; Follitropin alfa
- Indications Female infertility
- Focus Pharmacodynamics; Registrational
- Acronyms ESTHER-2
- Sponsors Ferring Pharmaceuticals
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
- 20 Jan 2017 This trial was completed in Belgium, European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History